{"name":"Faes Farma, S.A.","slug":"faes-farma-s-a","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"Hemorrane","genericName":"Hemorrane","slug":"hemorrane","indication":"Other","status":"discontinued"},{"name":"Bilastine 0%","genericName":"Bilastine 0%","slug":"bilastine-0","indication":"Other","status":"phase_2"},{"name":"Bilastine 0.4%","genericName":"Bilastine 0.4%","slug":"bilastine-0-4","indication":"Seasonal and perennial allergic rhinitis","status":"phase_2"},{"name":"Bilastine 0.6%","genericName":"Bilastine 0.6%","slug":"bilastine-0-6","indication":"Seasonal and perennial allergic rhinitis","status":"phase_2"},{"name":"Bilastine Ophthalmic Solution 0.6%","genericName":"Bilastine Ophthalmic Solution 0.6%","slug":"bilastine-ophthalmic-solution-0-6","indication":"Allergic conjunctivitis (ocular allergy symptoms)","status":"phase_3"},{"name":"Vehicle of Bilastine Ophthalmic Solution","genericName":"Vehicle of Bilastine Ophthalmic Solution","slug":"vehicle-of-bilastine-ophthalmic-solution","indication":"Allergic conjunctivitis","status":"phase_3"}]}],"pipeline":[{"name":"Hemorrane","genericName":"Hemorrane","slug":"hemorrane","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bilastine 0%","genericName":"Bilastine 0%","slug":"bilastine-0","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Bilastine 0.4%","genericName":"Bilastine 0.4%","slug":"bilastine-0-4","phase":"phase_2","mechanism":"Bilastine is an antihistamine that works by blocking the action of histamine, a substance in the body that causes allergy symptoms.","indications":["Seasonal and perennial allergic rhinitis","Chronic idiopathic urticaria"],"catalyst":""},{"name":"Bilastine 0.6%","genericName":"Bilastine 0.6%","slug":"bilastine-0-6","phase":"phase_2","mechanism":"Bilastine is an antihistamine that works by blocking the action of histamine, a substance in the body that causes allergy symptoms.","indications":["Seasonal and perennial allergic rhinitis","Chronic idiopathic urticaria"],"catalyst":""},{"name":"Bilastine Ophthalmic Solution 0.6%","genericName":"Bilastine Ophthalmic Solution 0.6%","slug":"bilastine-ophthalmic-solution-0-6","phase":"phase_3","mechanism":"Bilastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.","indications":["Allergic conjunctivitis (ocular allergy symptoms)"],"catalyst":""},{"name":"Vehicle of Bilastine Ophthalmic Solution","genericName":"Vehicle of Bilastine Ophthalmic Solution","slug":"vehicle-of-bilastine-ophthalmic-solution","phase":"phase_3","mechanism":"Bilastine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in ocular tissues.","indications":["Allergic conjunctivitis","Ocular allergic inflammation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"European Penny Stocks To Watch In March 2026 - simplywall.st","headline":"European Penny Stocks To Watch In March 2026","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-22","type":"pipeline","source":"simplywall.st","summary":"Faes Farma, S.A.'s (BME:FAE) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason? - simplywall.st","headline":"Faes Farma, S.A.'s (BME:FAE) Recent Stock Performance Looks Decent- Can Strong Fundamentals Be the Reason?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-12","type":"pipeline","source":"simplywall.st","summary":"The Bull Case For Faes Farma (BME:FAE) Could Change Following Higher Sales But Lower Net Income - simplywall.st","headline":"The Bull Case For Faes Farma (BME:FAE) Could Change Following Higher Sales But Lower Net Income","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNQThYbnMyWWdrNWRiemJicjUxV0U2UThMX0J5WEN2X29zd2FtZFV6enJwY25nZXo5dnEyb1M1NkV0NVdmOFZIWW9ZRWVSTC12cDBaMng4RGdLX0pCZ0t3amJkdmxvVzVTTGVOalRxSVlKRHI2NVFMVHpCaXp5dDhkRTEyeXc?oc=5","date":"2025-10-08","type":"pipeline","source":"Yahoo Finance","summary":"European Penny Stocks To Watch: Faes Farma Leads The Pack - Yahoo Finance","headline":"European Penny Stocks To Watch: Faes Farma Leads The Pack","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-07-26","type":"earnings","source":"simplywall.st","summary":"Faes Farma Reports Second Quarter 2025 Earnings - simplywall.st","headline":"Faes Farma Reports Second Quarter 2025 Earnings","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxPemlLTVVDMVdtcUlzZlNZNVFnWW56TmN0MllvVVVzVUx2NG9RdFpHV0J0RzZtc0tiaEhLMFlhUVN0bE1wRDJJeXIzUVhqYU5WbE5DZGd1NFV6d1RQSkd1VWlJMlhxc2w5UVlCdFBIQXBuekFTMXNpbV9FejI4SWhQS2NIeS1wemRfR0F3eWVDVmw0SUJSaUY2WFlqLVdkTkxEZnZxaTgtUVZHNEROMDI1Z0NjSXpxSUVrQWFNeGxueFluc0d1dHlldGFoS1JnM0xKVnc?oc=5","date":"2025-05-06","type":"earnings","source":"Investing.com","summary":"Faes Farma Q1 2025 presentation: Strong revenue growth offset by margin pressure - Investing.com","headline":"Faes Farma Q1 2025 presentation: Strong revenue growth offset by margin pressure","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxQNHdVaDhGOTRfYTM1NVU1N3R0LUlsYTh2TG0tcXZrM3hYWTVuTU9tMkZ4UlQ4eEJmMEhpV1prbTZvQnBUUkc0LS1UZ1dmZUV0T0xNbHYzUVJJSUtWdTNGVk5oRHYwRWwzekFGMHFUM2JIcmtrVzVrdkxFZ2FWYkV5UWIxOEYzTmRObVhPRWZfVTZkVTdHcE51WkM2RnhXN1E4Q0REVTBZR29idHNBNmZNRTNHaHJ0cXgzcnZZS2lXTVhGMUQzbERUNW55WDZmakZsNEhwaHNOSGV3RjJzMXYxTkRFZHFfN3lXTjJhSzB5amJYUDNkcTJzeFd2X3p0ei1haUlYZA?oc=5","date":"2021-09-20","type":"pipeline","source":"PR Newswire","summary":"Hikma and FAES Farma enter into exclusive licensing agreement for the commercialisation of Bilastine tablets in the US - PR Newswire","headline":"Hikma and FAES Farma enter into exclusive licensing agreement for the commercialisation of Bilastine tablets in the US","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4wJBVV95cUxOTWhERjZrdjNhZTF6WW5tYkdaR29yUkRod2NYWnEzUGYyeGhTenkzS3NCVV8xVk8yQU1VYjNobE5jdTY5S29EMU13QUx1T2ZjaVFTOEloNzdHQmZPeXZrSS02RmVJTlV4cndGcTZDZ0E1QXlNbVQ4U2lOSDMzMGk1QWlYMFpYZndfek1UUG9QMDA0N2NUeDFqaWFJdmc1U0RkTnJRdVlmeHFuT2gyNzFrNjViWm9oVVdUdlVIdG94eTRJWUJxVlVKbF80NGhLVFBnZnB4OXQ5elY5cmVrTWQ4LTR2SG9jNTZiV05xTWhMWUszb0R5dHI5Y0tFY1Z3QmhkYWpNWDJsS2ZNRjRlYjIzbE1sWDY0YTU5dmN3X2NISkEzZUltbk05d0ZEZGJvZVNLOWpMY1U5SHNINmRycGJNcEUxMUk3eVRvelpQS3A1NWZpN052S1pLcmxhM2hRenJaNXkw?oc=5","date":"2020-02-12","type":"pipeline","source":"PR Newswire","summary":"Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number of Countries in Latin America, Southern Africa, Central and Eastern Europe - PR ","headline":"Norgine B.V. Enters Into Exclusive Licence and Distribution Agreements for the Commercialisation of PLENVU® in a Number ","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiVEFVX3lxTE80SzI1VDJtN2xUVDFFZ0xodzc1TjRvSVQyWjh5YkdKNXA1bXpyYVlkR0VSRjNSSnhJRllQV3JTWTlnSWZwZy1HUVlfbmw2RUp3VUVPdg?oc=5","date":"2017-05-14","type":"pipeline","source":"sg.finance.yahoo.com","summary":"Faes Farma, S.A. (FAE.MC) stock price, news, quote and history - sg.finance.yahoo.com","headline":"Faes Farma, S.A. (FAE.MC) stock price, news, quote and history","sentiment":"neutral"}],"patents":[],"drugCount":6,"phaseCounts":{"discontinued":1,"phase_2":3,"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}